Jonathan Allan Sells 9,696 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 9,696 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the sale, the general counsel now directly owns 35,142 shares of the company’s stock, valued at $449,114.76. The trade was a 21.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK traded down $0.50 during mid-day trading on Tuesday, hitting $13.26. 1,053,661 shares of the stock traded hands, compared to its average volume of 749,634. The company has a market cap of $702.38 million, a price-to-earnings ratio of -6.31 and a beta of 0.95. The stock has a fifty day moving average price of $12.44 and a 200-day moving average price of $13.69. Stoke Therapeutics, Inc. has a 52 week low of $4.09 and a 52 week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The firm had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds have recently bought and sold shares of STOK. Barclays PLC lifted its holdings in shares of Stoke Therapeutics by 145.3% during the third quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after purchasing an additional 47,239 shares during the last quarter. Geode Capital Management LLC raised its stake in Stoke Therapeutics by 9.7% during the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after buying an additional 76,661 shares during the last quarter. Jane Street Group LLC raised its stake in Stoke Therapeutics by 338.2% during the third quarter. Jane Street Group LLC now owns 330,442 shares of the company’s stock valued at $4,061,000 after buying an additional 255,028 shares during the last quarter. State Street Corp boosted its holdings in Stoke Therapeutics by 8.6% in the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after acquiring an additional 137,145 shares in the last quarter. Finally, RTW Investments LP grew its stake in shares of Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after acquiring an additional 427,447 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms have recently weighed in on STOK. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Leerink Partners assumed coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $20.83.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.